FDA gives Bard marketing approval for endovascular stent graft

TriMed Staff | | Health Imaging | Screening
C. R. Bard has received approval from the FDA to market the Flair endovascular stent graft with an optimized delivery system.

The company said that its Flair graft is indicated to treat stenoses in synthetic arteriovenous bypass grafts. The device, comprised of a self-expanding Nitinol stent encapsulated within Bard’s proprietary ePTFE graft material, is marketed by the Bard Peripheral Vascular Division located in Tempe, Ariz.

Timothy M. Ring, chairman and CEO, said that the approval is the first step for the company in developing its position in the U.S. peripheral vascular stent market.

TriMed Staff

Related Content

Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.